Knowledge, Behaviour and Perceptions Affecting Control of HPV / HIV Co-Infection and Cervical Neoplasma Screening Among Patients with Cervical Cancer in Kenya

Article by Philip Kasawa Naluande¹, Praveen Thaggikuppe Krishnamurthy², Margaret Nyanchoki Keraka³

¹School of Clinical Research, Texila American University, Georgetown, Guyana, South America
²School of Clinical Research, Texila American University, Guyana, South America
³Dean School of Public Health, Kenyatta University, Nairobi, Kenya

Abstract

The main objective of this study was to assess how Knowledge, behavior and perceptions affect Cervical Cancer screening and the control of HIV/HPV Co-infection among patients with cervical cancer in Kenya. The following specific objectives guided the study; to weigh the knowledge, behavior, and perceptions on the understanding of the absorption of Cervical Cancer Screening and prevention strategies among women in Kenya. This was a cross-sectional, descriptive and quantitative comparative study of cervical neoplasia screening and control strategies among women attending Kenyatta National Hospital and Coast Provincial General Hospitals in Kenya. The study was conducted at the Coastal region of Kenya particularly Mombasa County and all parts of Nairobi County over a twelve-month period at the Coast Provincial General Hospital (CPGH) and Kenyatta National Hospital respectively. The target population for this work involved all female respondents who had tested positive for HIV and Cervical Cancer and have the results or they need further screening. Convenience sampling technique was used because of time constraints. Random sampling was used to identify participants. The study concludes that knowledge, behavior, and perceptions on absorption of Cervical Cancer Screening and prevention by women depend on initiatives that have been put in place to motivate and educate women on issues related to cancer screening. The study recommends that the need for community understanding of cervical cancer and the causal relationship between HPV and cervical cancer is usually poor, giving priority to continuing education on the significance of HPV prevention and periodic cervical Cancer screening.

Acronyms and Abbreviations

ACC Adenocarcinoma
ANC Antenatal Clinic
AOR Adjusted Odds Ratio
ARR Adjusted Related Risk
ASCUS Atypical Squamous Cells of Uncertain Significance
CDC Centre for Disease Control
CI Confidence Interval
CIN Cervical Intraepithelial Neoplasia
CxCa Cervical Cancer
DALY Disability Adjusted Life Year
DVI Direct Visual Inspection
EBRT Extend Beam Radiotherapy
ELISA Enzyme Linked Immunosorbent Assay
FIGO International Federation of Gynecology and Obstetrics
Introduction

Background information

One of the leading causes of morbidity and mortality in Kenya and the world at large is Human Papillomavirus (HPV). High-risk, oncogenic HPV types (featuring HPV 16 and HPV 18) are connected to 99.7% of all cervical cancers. Low-risk HPV types (HPV 6 and HPV 11) are accountable for incremental abnormal Pap test results, and almost all cases of genital warts. HPV is so prevalent that more than fifty percent of all sexually active people will be
tainted by the disease in their lifetime, however, it is the young sexually active women who bear the chief impact of both infection and clinical complications. Presently, there does not exist an effective HPV prevention strategies or efficient treatments for individuals with genital warts or cervical lesions in Kenya; the available treatments only focus on extracting the affected area consequently, recurrence is common. The government of Kenya is planning to avail to the health sector prophylactic vaccines in the near future. It is hoped that the vaccines will unquestionably reduce the morbidity and mortality associated with these infections.

A study conducted by CDC, (2004) revealed that roughly 20 million people living in America are infected with HPV and roughly 6.2 million new HPV infections develop each year. HPV is rampant among the sexually active populations since the infection is spread by skin-to-skin sexual contact. The study further reveals that Centers for Disease Control projects that at least half of the sexually active population will contract HPV at a given point in their lives, and at least 80% of women will contract the infection by the age of 50. In the United States, about 10% of the population have an active HPV infection, whereas 4% have an infection that results in cytological abnormalities, and an additional 1% have infection causing genital warts (Koutsy, 1997). Despite the small percentage of Americans revealed to have clinically visible genital warts, as many as 13% of americans attending STD clinics are reported to have genital warts (Koutsy, 1997). The greatest risk factors attributed to the infection include; gender, youth, and sexual activity, with the maximal rates being routinely found amongst the sexually active women aged 25 years and below. In a study conducted by Winer et al, 2003 that sampled 148 female university students who were sexually active and within 24 months 38.9% were infected by HPV. The most common HPV type detected was HPV 16 which had a cumulative infection rate of 10.4%, HPV 18 had a cumulative infection rate of 4.1% by the end of the 24 months. In a similar study conducted by Brown et al, (2005) examined a smaller sample of mid-adolescent women for a period of two years. At the end of the period, the results revealed that, 82% of the women were infected with HPV). DNA from both low-risk and high-risk HPV types has even been detected amongst women who engage in sexual activities with their fellow women counterparts, which is a population that was expected to have a low incidence of HPV infection (Marrazo et al; 2001). It should be observed that prevalence estimates vary due to the technique engaged in assessing the viral load; polymerase chain reaction analysis is a more sensitive detection method and yields higher rates of prevalence.

![Cumulative HPV infection](image)

**Figure 1.** Reveals the cumulative rate of HPV infection amidst college-aged women who were virgins at baseline. Adapted from (Winer et al 2003)

**Limitations**

The most important limitation of this study is the exclusion of genotyping tests to establish the common genotypes circulating within the population responsible for Cervical Cancer acquisition and progression due to financial constraints. It is important to recognize possible limitation of this study in terms of identification of specific genotypes responsible for acquisition of cervical cancer.
Thirdly, the other limitation to the study is the lack of viral load considering the fact viral load detection in blood is a good indicator of viral suppression as well as monitoring of drug effectiveness for HIV patients diagnosed with cervical cancer.

Materials and Method

Study site

The study was conducted at the Coastal region of Kenya particularly Mombasa County and all parts of Nairobi County over a twelve-month period at the Coast Provincial General Hospital (CPGH) and Kenyatta National Referral Hospital. The County of Mombasa and Nairobi have approximately 939,370 people and 3,138,369 respectively (KNBS, 2009). They are Cosmopolitan Centers with people of different races. The study sites a fair presentation of both the youth and the older generation. The Centers are chosen due to accessibility of VCT and free cervical malignant growth screening services being offered by the Ministry of Health (MOH) and also due to the fact that that they form the bulk of the population of both Mombasa county and Nairobi County.

Study design

A cross-sectional, descriptive and quantitative comparative study of cervical neoplasia screening, and control strategies among women attending Kenyatta National Hospital and Coast Provincial General Hospitals in Kenya.

Data collection techniques

Data was obtained from a total of 300 patients via face to face, patient interviews, patient records both outpatient and inpatient. The data collection was carried out by the researcher according to the schedule shown in the table. Only patients who consent will be scheduled in the study. Data was captured and cleaned then analyzed using the SPSS software.

Data management and analysis

Data quality was checked by pre testing questionnaires before use and data entered in the computers using double entry system. Queries were raised and resolved as soon as they were identified. Quality control was done to ensure reliability and validity of data. Data collected from patients at the Gynecological clinic, Oncology clinic, Radiotherapy clinic, Comprehensive Care Centre (CCC) and Pathology Laboratory was captured in the electronic data base and exported to excel work book 2010. Data analysis was done using SPSS Version 23.0 statistical software. Basic characteristics of the study samples were summarised using simple proportions and means, median and inter quartile ranges.

Further analysis was done to perform one way ANOVA comparing more than two means followed by Post hoc Student Newman Keul for multiple comparisons. Independent t-test was used to calculate if there was any significant difference between different groups. Data was presented by use of frequency distribution tables. In both statistics, 95% confidence level was used and all statistical tests were considered significant at $P < 0.05$. The data was presented qualitatively and quantitatively by way of narrative, description, tabulation and discussion.

Results

Mean comparison of the respondents

ANOVA

The study sought to determine the significance level between the groups in each of the objectives. From the findings, the f-calculated of Attitudes towards Cervical Cancer Screening was 2.792.
Table 1: ANOVA

|                          | Sum of Squares | df | Mean Square | F    | Sig. |
|--------------------------|----------------|----|-------------|------|------|
| Attitudes Towards Cervical Cancer Screening Between Groups | 536.503        | 30 | 17.883      | 2.792| .000 |
| Within Groups            | 1069.658       | 167| 6.405       |      |      |
| Total                    | 1606.162       | 197|             |      |      |

**T-test**

To test this, we concentrate on the 2-tailed value and compare it with 0.05. Values that are below 0.05 we reject the null hypothesis. From the results, the attitudes towards cervical cancer screening before education, the p-value was 0.001 for both equal variances assumed and equal variances not assumed. Therefore, we reject the null hypothesis.

Table 2. T- Test

|                          | F       | Sig. | t     | df  | Sig. (2-tailed) | Mean Difference | Std. Error Difference | 95% Confidence Interval of the Difference |
|--------------------------|---------|------|-------|-----|----------------|------------------|-----------------------|-----------------------------------------|
| Equal variances assumed  | 2.905   | .090 | 3.384 | 196 | .001           | 1.3508           | .3984                 | .56331 – 2.13685                       |
| Equal variances not assumed | 3.398 | .001 | 185.623 | .001 | 1.3508 | .39736 | .56615 – 2.13401 |

**Student-newman-keuls**

**Attitudes towards cervical cancer screening**

**Attitude toward second scanning**

From the ANOVA table, the p-value indicates that there was significant different between the groups on attitude towards Screening with a p-value of 0.041 which is less than 0.05. However, Student-Newman-Keuls indicates that there is no significant different between the groups. Therefore, Type I error levels are not guaranteed.

Table 3. ANOVA

|                          | Sum of Squares | df | Mean Square | F    | Sig. |
|--------------------------|----------------|----|-------------|------|------|
| Between Groups           | 9.301          | 3  | 3.100       | 2.813| .041 |
| Within Groups            | 213.790        | 194| 1.102       |      |      |
| Total                    | 223.091        | 197|             |      |      |
Table 4. Student-newman-keuls

| Student-Newman-Keuls<sup>a,b</sup> | If you were offered a free cervical cancer screen, would you be willing to be screened? | N   | Subset for alpha = 0.05 |
|------------------------------------|--------------------------------------------------------------------------------------|-----|------------------------|
| Unsure, many be willing            | 34                                                                                   | 2.5882 |
| No, would not be                   | 93                                                                                   | 2.6452 |
| Don’t know what cervical cancer is | 37                                                                                   | 3.0000 |
| Yes would be willing                | 34                                                                                   | 3.1471 |
| Sig.                               |                                                                                      | 0.076  |

Means for groups in homogeneous subsets are displayed

a. Uses Harmonic Mean Sample Size = 41.406.
b. The group sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not guaranteed

Reason for not willing to take second screening

From the ANOVA table, the p-value indicates that there was significant difference between the groups on willingness to be screened with a p-value of 0.000 which was less than 0.05. From Student-Newman-Keuls, it was inconvenient to get to a clinic and some didn’t know what was cervical cancer. Other reasons include; The test is human wanting are all not significantly differences while I don’t have time to attend for a test, The test will be painful and other groups are all significantly different because they are in different column which is column 1, 2, 3 and 4. Therefore Type I error levels are not guaranteed.

Table 5. ANOVA

|                     | Sum of Squares | df  | Mean Square | F       | Sig.  |
|---------------------|----------------|-----|-------------|---------|-------|
| Between Groups      | 153.330        | 5   | 30.666      | 51.356  | .000  |
| Within Groups       | 114.649        | 192 | .597        |         |       |
| Total               | **267.980**    | 197 |             |         |       |

Table 6. Student-Newman-Keuls

| Student-Newman-Keuls<sup>a,b</sup> | What will make you not to be willing or interested in taking cervical cancer screening? | N   | Subset for alpha = 0.05 |
|------------------------------------|--------------------------------------------------------------------------------------|-----|------------------------|
| It’s inconvenient to get to a clinic | 34                                                                                   | 1.1765 |
| I don’t know what it’s for          | 24                                                                                   | 1.3750 |
|                                   |                                                                                      | 1.3750 |
| Other reasons                      | 81                                                                                   | 1.7284 |
|                                   |                                                                                      | 1.7284 |
| The test is human wanting          | 19                                                                                   | 2.0526 |
| The test will be painful           | 18                                                                                   | 3.2222 |
| I don’t have time to attend for a test | 22                                                                                   | 4.0000 |
| Sig.                               |                                                                                      | .362 |
|                                   |                                                                                      | 1.05 |
|                                   |                                                                                      | 1.137 |
|                                   |                                                                                      | 1.000 |
|                                   |                                                                                      | 1.000 |

Means for groups in homogeneous subsets are displayed

a. Uses Harmonic Mean Sample Size = 25.309.
b. The group sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not guaranteed

Individual cervical cancer

From the ANOVA table, the p-value indicates that there was significant difference between the groups on how the patient think are risks for cervical cancer with a p-value of
0.024 which is less than 0.05. However, Student-Newman-Keuls indicates that there is no significant different between the groups. Therefore, Type I error levels are not guaranteed.

### Table 7. ANOVA

|                | Sum of Squares | df | Mean Square | F    | Sig. |
|----------------|----------------|----|-------------|------|------|
| Between Groups | 40.329         | 2  | 20.165      | 3.799| 0.024|
| Within Groups  | 1034.923       | 195| 5.307       |      |      |
| Total          | 1075.253       | 197|             |      |      |

### Table 8. Student-Newman-Keuls

|                          | N  | Subset for alpha = 0.05 |
|--------------------------|----|------------------------|
| Do you think you are at risk for cervical cancer | 152 | 7.2171 |
| Yes                      | 27 | 8.2222 |
| Don’t know               | 19 | 8.3684 |
| No                       |    | 122                    |

Means for groups in homogeneous subsets are displayed
a. Uses Harmonic Mean Sample Size = 31.170.

Attitude towards Healthy Woman and Screening for Cervical Cancer

From the ANOVA table, the p-value indicates that there was no significant different between the groups on whether the patient think healthy woman, who feed well, need to be screened for cervical cancer with a p-value of 0.064 which is less than 0.05. Similarly, Student-Newman-Keuls indicates that there is no significant difference between the groups. Therefore, Type I error levels are not guaranteed.

### Table 9. ANOVA

|                | Sum of Squares of df | Mean Square | F    | Sig. |
|----------------|----------------------|-------------|------|------|
| Between Groups | 1.002                | 2           | .501 | 2.789| .064|
| Within Groups  | 35.038               | 195         | .180 |      |      |
| Total          | 36.040               | 197         |      |      |      |

### Table 10. Student-Newman-Keuls

|                          | N  | Subset for alpha = 0.05 |
|--------------------------|----|------------------------|
| Do you think a healthy woman, who feeds well, need to be screened for cervical cancer | 19 | 1.0000 |
| No                       | 21 | 1.0000 |
| Don’t know               | 158| 1.1772 |
| Yes                      |    | 262                    |

Means for groups in homogeneous subsets are displayed
a. Uses Harmonic Mean Sample Size = 28.148.

Individual Cervical Cancer Information Sharing

From the ANOVA table, the p-value indicates that there was significant different between the groups on whether the patient have ever talked with their mother, daughter or friends about cervical cancer with a p-value of 0.043 which is less than 0.05. However, Student-
Newman-Keuls indicates that there is no significant different between the groups. Therefore Type I error levels are not guaranteed.

Table 11. ANOVA

|                      | Sum of Squares | df | Mean Square | F    | Sig. |
|----------------------|----------------|----|-------------|------|------|
| Between Groups       | 2.489          | 2  | 1.244       | 3.189| .043 |
| Within Groups        | 76.097         | 195| .390        |      |      |
| Total                | 78.586         | 197|             |      |      |

Table 12. Student-Newman-Keuls

| Have you ever talked with your mother, daughter or friends about cervical cancer | N    | Subset for alpha = 0.05 |
|----------------------------------------------------------------------------------|------|------------------------|
| No                                                                               | 23   | 1.0435                 |
| Don’t know                                                                       | 21   | 1.1905                 |
| Yes                                                                              | 154  | 1.3701                 |
| Sig.                                                                             |      | 103                    |

Means for groups in homogeneous subsets are displayed

a. Uses Harmonic Mean Sample Size = 30.741.

b. The group sizes are unequal. The harmonic mean of the group sizes is used. Type I error levels are not guaranteed

Discussion

The study discussed the respondents’ response and findings according to the questionnaires given to them.

Attitudes towards cervical cancer screening before educational intervention

Knowledge and Awareness Levels after Educational Intervention with 3.347 and Attitudes towards Cervical Cancer Screening Educational was 3.897 and the f- tabulated is 1.527 hence there was significant different between the groups. For knowledge and awareness levels after educational intervention the p-value for both equal variances assumed and 0.033 and 0.029 respectively, therefore we reject the null hypothesis. The p-value for attitudes towards cervical cancer screening educational is 0.282 and 0.287 which is greater than 0.05. We therefore accept the null hypothesis. Lastly the p-value for general health was 0.057 and 0.053 for both equal variances assume and equal variances not assumed respectively therefore we accept the null hypothesis. In all of the outcomes there was not much significance difference in the mean. According to a study conducted in Western Kenya that discovered the following, first, self-reported HIV was linked with increased CC screening attendance and secondly not all women who admitted living with HIV undertook screening services, this finding highlights the significance of education among the high-risk group of women (Orango’o et al; 2016). In order to ensure proper conveyance of information and retention of patients in health care is through laying a strong foundational relationship between the provider and patient, particularly those who have many medical and social needs (Fletcher et al; 2014).

Conclusion

The study concludes that knowledge, behavior, and perceptions on absorption of Cervical Cancer Screening and prevention by women depend on initiatives that have been put in place to motivate and educate women on issues related to cancer screening. When there are good strategies of education the awareness level and knowledge increase therefore reduces the risk associated with Cervical Cancer.
**Recommendations**

The recommendations of this study can be summed up based on Kenya health Care reforms. Outreach, community mobilization, health education (including extensive sexuality education) and counseling are vital elements of an efficient program for the prevention and control of cervical cancer that guarantees elevated coverage of vaccination and screening and elevated therapy adherence (75). Also, vital elements of the HIV reaction are community outreach, mobilization and commitment. Using HIV infrastructure can provide both programs with resource optimization and extra efficiencies. Reducing morbidity and mortality from cervical cancer needs better schooling and interaction. Community understanding of cervical cancer and the causal relationship between HPV and cervical cancer is usually poor, giving priority to continuing education on the significance of HPV prevention and periodic cervical screening.

**Disclaimer**

The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Kenyatta University nor Clinical and Laboratory Standards Institute. Use of trade names is for identification purposes only and does not constitute endorsement by Kenyatta University nor Clinical and Laboratory Standards Institute.

**References**

[1]. Adamson P.C, Huchko M.J, Moss A.M, Kinkel H.F, Medina-Marino A. (2015). Acceptability and accuracy of cervical cancer screening using a self-collected tampon for HPV messenger-RNA testing among HIV-infected women in South Africa. *PLoS One.*; 10(9): e0137299.

[2]. Addison, A., Dagin, A., Tadela, E., Addison, A., Mussie, A. and Filmon, K. (2015). CD4 Cell counts trends after commencement of antiretroviral therapy among HIV infected patients in Tigray, Northern Ethiopia. A Retrospective Cross-Sectional Study. *PLos ONE, 10(9)* e0122583 http://do/i.org/10.1371/journal.pone.0122583

[3]. Adler DH, Wallace M, Bennie T, et al. (2014). Cervical dysplasia and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected adolescent females in South Africa. *Infect Dis Obstet Gynecol.* 2014;498048.

[4]. Adler D.H, Wallace M, Bennie T, et al. (2014). Cervical dysplasia and high-risk human papillomavirus infections among HIV-infected and HIV-uninfected adolescent females in South Africa. *Infect Dis Obstet Gynecol;* 2014:498048.

[5]. Africa: an association between highly prevalent infectious diseases (2010). A systematic review and meta-analysis. *Int J Infect Dis* 14(12): e1024–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20870439

[6]. Anderson J, Wysong M, Estep D, et al. (2015). Evaluation of cervical cancer screening programs in Côte d’Ivoire, Guayas Socio-demographic and Tanzania: effect of HIV status. *PLoS One.* 2015; 10(9): e0139242.

[7]. Arbyn M, Verdoort F, Snijders PJ, et al. (2014). Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. *Lancet Oncol.* 2014; 15(2):172–183.

[8]. Ault, K.A. (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. *The Lancet;* 369: 9576, 1861-1868.

[9]. Bayu H, Berhe Y, Mulat A, Alemu A. (2015). Cervical cancer screening service uptake and associated factors among age eligible women in Mekelle Zone, Northern Ethiopia, A community-based study using health belief model. *PLoS One;* 11(3): e0149908.

[10]. Bendacid, E., Philip, G., Ammie, T., Douglas, K. O. and Andrew, Z. (2011). Cost effectiveness of antiretroviral regimens in the World Health Organization, Treatment Guidelines: A South African analysis. *Journal of Acquired Immunodeficiency Syndrome* 25: 211-220.

[11]. Between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control. 2010; 21(3):433–43.

[12]. Bosch F.X, Broker T.R, Forman D, et al. (2013). Comprehensive control of human papillomavirus infections and related diseases.
[13]. Brown DR, Shew ML, Qadadri B, et al. (2005). A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. The Journal of Infectious Diseases; 191 (2):182–192.

[14]. Bukirwa A, Mutyoba JM, Mukasa B.N et al. (2015). Motivations and barriers to cervical cancer screening among HIV infected women in HIV care: a qualitative study. BMC Womens Health.15:82.

[15]. Cancer IIA/Ro. GLOBOCAN (2012): Estimated cancer incidence, mortality and prevalence worldwide in 2012. In: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx, editor.

[16]. Cattani P, Zamoni GF, Ricci C, et al. (2009). Clinical performance of human papillomavirus E6 and E7 mRNA testing for high-grade lesions of the cervix. J Clin Microbiol; 4 7(12):3895–3901.

[17]. Christine Danel, Delphine Gabillard, Jerome Le Carro, Xavier Anglaret1, Raoul Moh, Serge Eholie, Hervé Ménan, Anani Badje, Gerard Kouame JBN. Early ART and IPT in HIV-Infected African Adults with High CD4 Count (Temprano Trial) (2015). Conference on Retroviruses and Opportunistic Infections (CROI) [Internet]. Seattle, Washington, USA: Available from: http://www.croiconference.org/sessions/early-art-andipt- hiv-infected-african-adults-high-cd4-count-temprano-trial.

[18]. Chung MH, McKenzie K, De Vuyst H, et al. (2013). Comparing papanicolaou smear, visual inspection with acetic acid and human papillomavirus cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy. AIDS:27 (18): 2909–2919.

[19]. Clifford G.M, Franceschi S, Keiser O, et al. (2016). Immunodeficiency and the risk of cervical intraepithelial neoplasia 2/3 and cervical cancer: a nested case-control study in the Swiss HIV cohort study. Int J Cancer; 138 (7):1732–1740.

[20]. Cronjé H.S (2004). Screening for cervical cancer in developing countries. Int J Gynecol Obstet; 84(2):101–108.

[21]. DeGregorio GA, Bradford LS, Manga S, et al. (2016). Prevalence, predictors and same day treatment of positive VIA enhanced by digital cervicography and histopathology results in a cervical cancer prevention program. PLoS One. 2016; 11(6): e0157319.

[22]. Denny L, Anorlu R. (2012). Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev; 21(9):1434–1438.

[23]. Denny L, de Sanjose S, Muthe M. (2016). Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries. Lancet.

[24]. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN (2008). Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: https://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php. Accessed January 13, 2017.

[25]. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN (2012). Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Available from: http://globocan.iarc.fr. Accessed July 22, 2016.

[26]. Fink MJ, Frucher RG, Maiman M, et al. (1994). The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in HIV-seropositive women. Gynecol Oncol. 55 (1):133–137.

[27]. Finnhaber C, Mao L, Levin S, et al. (2015). Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa. J Low Gen Tract Dis; 19 (1):7–11.

[28]. Finnhaber C, Mayisela N, Mao L. (2013). Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One. 2013; 8 (1): e53494.

[29]. Fletcher F.E, Buchberg M, Schover L.R. (2014). Perceptions of barriers and facilitators to cervical cancer screening among low-income, HIV-infected women from an integrated HIV clinic. AIDS Care; 26(10): 1229–1235.

[30]. Frazier EL, Sutton MY, Tie Y, McNaghten AD, Blair JM, Skarbinski J. (2016). Screening for cervical cancer and sexually transmitted diseases among HIV-infected women. J Womens Health (Larchmt). 2016; 25(2): 124–132.

[31]. Gakidou E, Nordhagen S, Obermeyer Z. (2008). Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 5(6): e132.

[32]. Ho GY, Kadish AS, Burk RD, et al. (1998). HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. International Journal of Cancer; 78:281-285.
[33]. Hogewoning C.J, Bleeker M.C, van den Brule A.J, et al. (2003). Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. *International Journal of Cancer*. 2003; 107(5):811–816.

[34]. Huchko MJ, Sneden J, Leslie HH, et al. (2014). A comparison of two visual inspection methods for cervical cancer screening among HIV-infected women in Kenya. *Bull World Health Organ*;92(3):195–203.

[35]. Huchko MJ, Sneden J, Sawaya G, et al. (2015). Accuracy of visual inspection with acetic acid to detect cervical cancer precursors among HIV-infected women in Kenya. *Int J Cancer*,136(2):392–398.

[36]. Jemal A, Bray F, Forman D, et al. (2012). Cancer burden in Africa and opportunities for prevention. Cancer; 118 (18):4372-84.

[37]. Jemal A, Center MM, DeSanctis C, Ward EM. (2010). Global patterns of cancer incidence and mortality rates and trends. *Cancer Epidemiol Biomarkers Prev*; 19 (8):1893–1907.

[38]. Keller MJ (2015). Screening for human papillomavirus-associated cervical disease in HIV-infected women. *Top Antivir Med*; 23(4): 142–145.